The U.S. Food and Drug Administration today (Friday) began discussing the question of approving the third dose of Pfizer vaccine for corona 16 and older.
The head of the health services in Israel, Dr. Elrai Price, presented the efficiency data of the booster in Israel.
The discussion revolves around, among other things, the question of whether there is enough evidence that a third vaccine cream is also needed for young people, while there is already enough evidence that it increases protection for those aged 65 and over.
Meanwhile, a new study by a team of researchers from the Weizmann Institute of Science, the Ministry of Health, the Technion, the Hebrew University, the Gartner Institute at Sheba Medical Center and the KI Institute shows high efficacy of a third Pfizer vaccine - both in preventing and preventing serious disease.
Findings published in the New England Journal of Medicine show that a third dose has more than ten times improved the immune protection of its recipients compared to those who were vaccinated with only two doses five months ago or more.
